Evermay Wealth Management LLC Buys 628 Shares of Johnson & Johnson (NYSE:JNJ)

VaselineSeptember 5, 2024

0 4 minutes read

Evermay Wealth Management LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 7.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 9,532 shares of the company’s stock after buying an additional 628 shares during the period. Evermay Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,393,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Autumn Glory Partners LLC boosted its stake in Johnson & Johnson by 17.4% in the second quarter. Autumn Glory Partners LLC now owns 21,645 shares of the company’s stock worth $3,164,000 after purchasing an additional 3,204 shares during the period. Whalen Wealth Management Inc. purchased a new position in Johnson & Johnson in the second quarter valued at $398,000. Allegheny Financial Group LTD boosted its stake in shares of Johnson & Johnson by 16.6% during the second quarter. Allegheny Financial Group LTD now owns 14,832 shares of the company’s stock worth $2,168,000 after buying an additional 2,112 shares during the period. Comgest Global Investors SAS boosted its stake in Johnson & Johnson by 6.8% during the second quarter. Comgest Global Investors SAS now owns 1,987,954 shares of the company’s stock worth $290,559,000 after buying an additional 127,133 shares during the period. Finally, Hemington Wealth Management boosted its stake in Johnson & Johnson by 0.8% during the second quarter. Hemington Wealth Management now owns 17,892 shares of the company’s stock worth $2,615,000 after buying an additional 139 shares during the period. Institutional investors own 69.55% of the company’s shares.

Analyst upgrades and downgrades

JNJ has been the subject of several recent analyst reports. Daiwa Capital Markets cut shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $160.00 to $150.00 in a research note on Tuesday, July 23. TD Cowen decreased their price objective on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Royal Bank of Canada reissued an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a research note on Tuesday, July 30th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 16th. Finally, Daiwa America lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Moderate Buy” and a consensus price target of $173.21, according to MarketBeat.com.

Want more great investment ideas?

Read the latest stock analysis on Johnson & Johnson

Johnson & Johnson stocks rose 0.1%

NYSE:JNJ opened at $167.27 on Thursday. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The company has a 50-day moving average of $156.82 and a 200-day moving average of $153.70. The firm has a market cap of $402.57 billion, a PE ratio of 10.43, a price-to-earnings-growth ratio of 2.73 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07, and a quick ratio of 0.85.

Johnson & Johnson (NYSE:JNJ – Get Your Free Report ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. In the same period last year, the company earned $2.80 per share. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. As a group, research analysts anticipate that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson announces dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a dividend of $4.96 on an annualized basis and a yield of 2.97%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Insiders place their bets

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC’s website. 0.16% of shares are currently held by corporate insiders.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures and sells various health products worldwide. The company’s Innovative Medicines segment offers products for various therapeutic areas such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis; infectious diseases including HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders and schizophrenia; oncology, such as prostate cancer, hematological malignancies, lung cancer and bladder cancer; cardiovascular and metabolic, including thrombosis, diabetes and macular degeneration; and pulmonary hypertension including pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.